任菁
REN Jing

• 1:广州市花都区胡忠医院(妇幼保健院)药剂科

摘要(Abstract)：

目的探讨不同剂量的重组人促红细胞生成素(rh EPO)在极低出生体重儿(VLBWI)脑损伤治疗中的临床效果及安全性。方法选取2014年10月~2016年10月在本院儿科收治的确诊为脑损伤的VLBWI 118例,随机分为大剂量组45例、小剂量组43例、对照组30例。大剂量组及小剂量组在出生后7 d内分别给予rh EPO 1 000 U·kg~(-1)、500 U·kg~(-1)静脉注射,连用3 d,对照组只给予常规对症治疗。观察各组治疗效果及安全性。结果大剂量组血清中EPO、S100B、IL-6水平分别与小剂量组、对照组比较,差异有统计学意义(P<0.05);小剂量组各项指标和对照组比较,差异无统计学意义(P>0.05);大剂量组NBNA评分、6个月及12个月PDI、MDI评分分别与对照组比较,差异有统计学意义,P<0.05;各组12个月PDI、MDI评分与6个月时指标比较,差异均有统计学意义(P<0.05);大剂量组和其他两组比较,12个月时PDI、MDI改善更明显(P<0.05)。结论大剂量rh EPO在VLBWI脑损伤治疗中效果优于小剂量,且较安全,临床可以推广应用。
OBJECTIVE To investigate the clinical efficacy and safety of different doses of recombinant human erythropoietin( rh EPO) in the treatment of very low birth weight infants( VLBWI). METHODS From October 2014 to October 2016,118 cases of brain injury of very low birth weight infant in our hospital,were randomly divided into 3 groups: high-dose group( 45 cases),low-dose group( 43 cases) and control group( 30 cases). Within 7 d after birth,high-dose group and low-dose group were given rh EPO 1 000U·kg~(-1),500 U·kg~(-1)intravenously for 3 d. The control group only received routine symptomatic treatment. The therapeutic effect and safety were observed. RESULTS The levels of EPO,S100 B and IL-6 in serum of high-dose group were significantly different with those of control group( P<0.05); there was no significant difference between the low-dose group and the control group( P>0.05); NBNA score,6 months and 12 months PDI,MDI scores of high-dose group were significantly different with those of the control group( P <0.05); the PDI score and MDI score of 12 months were significantly different with those of 6 months( P< 0.05); 12 months PDI,MDI improvement of the high-dose group was more obvious than those of the other two groups( P < 0. 05). CONCLUSION High dose of rh EPO in the treatment of VLBWI brain injury is better than low dose. It is safe and can be widely used in clinic.

关键词(KeyWords)： 重组人红细胞生成素;脑损伤;极低出生体重儿;不同剂量
recombinant human erythropoietin;brain injury;very low birth weight infant;different doses

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 任菁
REN Jing

参考文献(References)：

• [1]常立文,刘皖君,廖财绪,等.不同剂量的重组人类促红细胞生成素在防治早产儿贫血中的应用[J].中华儿科杂志,2000,38(11):707-708.
• [2]左相荣.促红细胞生成素的神经保护与视网膜保护作用的研究进展[J].河北医科大学学报,2012,33(2):246-248.
• [3]Sanchis-Gomar F,Perez-Quilis C,Lippi G,et al.Erythropoietin receptor(EpoR)agonism is used to treat a wide range of disease[J].Mol Med,2013,19(4):62-64.
• [4]Chamorro M E,Wenker S D,Vota D M,et al.Erythropoietin receptor(EpoR)agonism is used to treat a wide range of disease[J].Biochim Biophys Acta,2013,1833(8):1960-1968.
• [5]王澄澄,褚航,朱敏桥,等.基于神经推理的多维空间感知单眼区域立体视的临床研究探索[J].中国斜视与小儿眼科杂志,2013,21(3):42-44.
• [6]周翔,韩静,罗小燕.早期大剂量EPO对早产儿脑发育的保护作用研究[J].中华全科医学,2011,9(7):1044-1045.
• [7]黄晓虹,贺娟,陈晓文.影响早产儿20项行为神经评分的危险因素分析[J].中国小儿急救医学,2011,18(2):118-119.
• [8]肖梅.新生儿缺氧缺血性脑病的诊治进展及相关问题[J].临床儿科杂志,2010,25(3):179-182.
• [9]李锦芬.早产儿脑损伤及相关高危因素分析[D].苏州:苏州大学,2014.
• [10]金越,汤汉红,金全,等.脑损伤早产儿脐血S-100B蛋白和行为神经评分变化趋势的研究[J].中国妇幼保健,2015,30(33):5788-5789.
• [11]张素娥,薛辛东,富建华.早产儿脑蛋白损伤的影响学研究进展[J].中国新生儿科杂志,2011,26(5):350-352.
• [12]刘敏.早产儿脑损伤的诊断与治疗[J].中国小儿急救医学,2013,20(6):555-559.
• [13]谢爱兰,陈尚勤,林尚怡,等.脐血S100B蛋白在早产儿脑损伤中的临床意义及预测价值[J].现代实用医学,2010,22(4):20-22.
• [14]Chamorro M E,Wenker S D,Vota D M,et al.Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative[J].Biochim Biophys Acta,2013,1833(8):1960-1968.
• [15]雷鹏,张兴超,彭龙锋,等.促红细胞生成素对重型颅脑损伤伴休克大鼠炎症因子IL-1及S-100B蛋白表达影响的实验研究[J].中华创伤杂志,2007,23(9):675-677.
• [16]Wojtczak-Soska K.Lelonek M.S-100B protein:An early prognostic marker after cardiac arrest[J].Cardiol J,2010,17(5):532-536.
• [17]陈志钧,夏博,汪泽,等.外展神经麻痹的病因合临床表现探讨[J].中国斜视与小儿眼科杂志,2013,21(1):25-27.
• [18]单继艳.不同剂量重组人促红细胞生成素治疗早产儿脑损伤疗效及安全性探讨[D].南京:江苏大学,2016.